AZN241004P75000
- 0.05
- -0.03-37.50%
AstraZeneca Newsroom
Eli Lilly and Co (LLY.US) explores new uses for 'weight-loss miracle drug' Zepbound, aiming to reduce the incidence of high-risk populations such as diabetes.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
Daiichi Sankyo/AstraZeneca (AZN.US) heavy-duty ADC obtains FDA priority review qualification.
The USA FDA is expected to complete the review in the first quarter of 2025.
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could Be Next
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
AstraZeneca Updates Share Voting Rights
CytoSorbents Spikes on FDA Submission for DrugSorb-ATR
CytoSorbents Has Submitted Its DrugSorb-ATR Medical Device De Novo Marketing Application To The FDA, To Reduce Severity Of Perioperative Bleeding In Patients On Ticagrelor (Brilinta, AstraZeneca) Undergoing Coronary Artery Bypass Graft Surgery
ENHERTU (Fam-trastuzumab Deruxtecan-nxki) Granted Priority Review in the US for Patients With HER2-low or HER2-ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
AstronauTx Appoints Jane Rhodes as Chief Executive Officer and Expands Executive Team
AstraZeneca, Daiichi Sankyo's Breast Cancer Treatment Enhertu Accepted for US Priority Review
Citi Sticks to Their Buy Rating for AstraZeneca (AZN)
AstraZeneca (AZN): A Strong Buy as FDA Approves Key Cancer Treatments and Revenue Surges
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Erste Group Downgrades AstraZeneca(AZN.US) to Hold Rating
Seizing the opportunities for the development of the sharing economy, astrazeneca helps to promote the construction of a highland of innovation in the digital medical industry.
Hangzhou, September 30, 2024 / PRNewswire / -- On September 25, the global Digital Trade Expo, the only one themed on digital trade in China, referred to as "the Digital Trade Expo" hereinafter, kicked off in Hangzhou. Astrazeneca participated deeply in the Digital Trade Expo for the third consecutive year, bringing a variety of cutting-edge digital medical innovations with partners for release and display, actively engaging in collaborative exchanges, and jointly contributing to the establishment of China's digital medical industry innovation hub. At this Digital Trade Expo, as the unit presiding over the Digital Medical Health Industry Professional Committee, Astrazeneca supported the organization of the Digital Medical Health Industry Matchmaking Meeting and a series of activities. Astrazeneca
European healthcare stocks ended their October winning streak, causing concerns for companies like novo-nordisk a/s (NVO.US) and other pharmaceutical companies.
European medical care stocks are about to end their longest rising trend since March 2010, due to market concerns about novo-nordisk a/s's upcoming third-quarter performance, as well as experimental drug updates from astrazeneca and roche.
DHL's Unit, Alexion to Partner on Sustainable Pharmaceutical Product Transport in Europe
Astrazeneca (AZN.US) announced the application for listing of the antisense therapy Eplontersen in China.
The CDE website shows that Astrazeneca (AZN.US)'s antisense therapy Eplontersen (IONIS-TTR-LRx, brand name: Wainua) has applied for listing in China.
Is AstraZeneca PLC (AZN) the Best Cheap Growth Stock to Buy According to Analysts?
Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations